Notch transcription activation complex (NTC)

The Notch transcription activation complex (NTC) is the primary nuclear effector of the Notch signaling pathway, a highly conserved mechanism for cell-to-cell communication that governs cell fate decisions. The complex is a ternary assembly consisting of the Notch intracellular domain (NICD), the DNA-binding protein CSL (also known as RBPJ), and the co-activator Mastermind-like (MAML) (PMID: 16929290). Formation of the NTC occurs following the proteolytic cleavage of the Notch receptor by gamma-secretase, which releases the NICD to translocate into the nucleus. Once inside, NICD binds to CSL, displacing co-repressors and recruiting MAML to initiate the transcription of downstream target genes such as the HES and HEY families (UniProt P46531). Dysregulation or constitutive activation of this complex is a major driver in several malignancies, most notably T-cell acute lymphoblastic leukemia (T-ALL) and various solid tumors. Modern therapeutic strategies focus on small molecules and stapled peptides designed to specifically disrupt the protein-protein interactions within the NTC, offering a potentially more targeted approach with fewer side effects than broad-spectrum gamma-secretase inhibitors (PMID: 29038244).

Other names

NICD/CSL/MAML complexNotch transcriptional complexRBPJ/NICD/MAML complexNotch ternary complexNotch intracellular domain transcriptional complex

The complex acts as a transcriptional activator that initiates the expression of Notch target genes. Therapeutic agents targeting this complex, such as CB-103, function by disrupting the protein-protein interactions between the Notch intracellular domain (NICD), the DNA-binding protein CSL (RBPJ), and the co-activator Mastermind-like (MAML), thereby preventing the assembly of the active transcriptional machinery (PMID: 29038244).